<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456506</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU5010</org_study_id>
    <nct_id>NCT02456506</nct_id>
  </id_info>
  <brief_title>Hyperfractionated Intensity-modulated Radiotherapy (IMRT) Versus Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.</brief_title>
  <official_title>Multiple Centre, Randomised, Controlled Trial of Hyperfractionated IMRT and Conventional Fraction IMRT for Patients With Loco-regionally Recurrent Nasopharyngeal Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the hyperfractionated IMRT in the treatment of patients with locally
      recurrent nasopharyngeal carcinoma. Half of participants will receive hyperfractionated IMRT,
      while the other half will receive conventional fraction IMRT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Local recurrence is one of the most challenging issues faced with nasopharyngeal carcinoma
      (NPC) patients. 8.4% to 10.9% of the patients developed recurrent diseases at the primary
      or/and regional site after definitive radiotherapy. Although some patients with limited
      recurrent lesions underwent surgery, the main treatment for these recurrent NPC patients was
      still re-irradiation.

      Multiple retrospective and prospective studies have reported: under the condition of
      conventional fraction IMRT with the total dose of 60 gray (Gy) (division 27 times, once a
      day, every 2.2Gy), you can get a better local tumor control rate and survival outcome.
      However, the patients still underwent some severe late complications including nasopharyngeal
      necrosis, nasopharyngeal bleeding, temporal lobe necrosis, with the incidence rates of 28.8%,
      18.6%, 20.3%, respectively. Approximately 50% of recurrent NPC patients died of these severe
      late complications, significantly compromising the overall survival rate of the patients.
      Previous studies showed that hyperfractionated radiotherapy could reduce severe late
      complication rates significantly, without affecting the local control rate. Indeed, we found
      that under the condition of equal irradiation time and tumor equivalent dosage between
      hyperfractionated IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy,
      irradiation interval of 6-8 hours) and conventional fraction IMRT (total dose of 60Gy,
      division 27 times, once a day, every 2.2Gy), the normal late responding tissues equivalent
      dosage( EQD2) significantly decreased compared with conventional fraction IMRT. Therefore,
      the use of hyperfractionated IMRT is expected to decrease severe late complications rates,
      thereby improving the quality of life and overall survival of patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severe late complications rate</measure>
    <time_frame>2 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Loco-regional relapse free survival rate</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis free survival rate</measure>
    <time_frame>3 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <condition>Mortality</condition>
  <condition>Quality of Life</condition>
  <condition>Complications</condition>
  <arm_group>
    <arm_group_label>Hyperfractionated IMRT Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMRT (total dose of 65Gy, division 54 times, twice a day, once 1.2Gy, irradiation interval of 6-8 hours)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Fraction IMRT Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IMRT (total dose of 60Gy, division 27 times, once a day, every 2.2Gy)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hyperfractionated IMRT</intervention_name>
    <arm_group_label>Hyperfractionated IMRT Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Conventional Fraction IMRT</intervention_name>
    <arm_group_label>Conventional Fraction IMRT Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically approved WHO III patients received radical radiotherapy initially
             before recurrence (irradiation dosage &gt; 66 Gy).

        the interval time between initial treatment and relapse more than 1 year. recurrent Tumor
        stage2-4(rT2-4) Node stage0-2(rN0-2) Metastasis stage0(rM0) (rT2-4N0-2M0), overall stage
        II-IVa according to 2009 American Joint Committee on Cancer (AJCC/UICC) Tumor, Node, and
        Metastasis (TNM) staging system.

        a Karnofsky performance status (KPS) score more than 70.

        Exclusion Criteria:

          -  a history of previous or synchronous malignant tumors. recurrent Node stage3(rN3),
             recurrent Metastasis stage1(rM1) according to 2009 AJCC/UICC TNM staging system.

        positive surgical margin after neck dissection. patients suffered with severe mental
        illness. severe diseases of the lung and cardiovascular system. severe hepatic and renal
        dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi Pan, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Guangdong General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dong-Ping Chen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Cancer Center of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <phone>86-20-8734-3361</phone>
    <email>chmingy@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui You, MD</last_name>
    <phone>86-20-8734-3361</phone>
    <email>yourui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-yuan Chen, MD, PhD</last_name>
      <phone>86-20-8734-3361</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Rui You, MD, PhD</last_name>
      <phone>86-20-13580439820</phone>
      <email>yourui@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Cummings BJ. Benefits of accelerated hyperfractionation for head and neck cancer. Acta Oncol. 1999;38(2):131-6. Review.</citation>
    <PMID>10227432</PMID>
  </reference>
  <reference>
    <citation>Jereczek-Fossa BA, Morra A, DeBraud F, Alterio D, Mazzetta C, Rocca A, Catalano G, Bianchi L, Pasetti M, Chiesa F, Bruschini R, Orecchia R. Hyperfractionated radiotherapy in locally advanced nasopharyngeal cancer. An analysis of 43 consecutive patients. Strahlenther Onkol. 2004 Jul;180(7):425-33.</citation>
    <PMID>15241530</PMID>
  </reference>
  <reference>
    <citation>Jian JJ, Cheng SH, Tsai SY, Yen KC, Chu NM, Chan KY, Tan TD, Cheng JC, Lin YC, Leu SY, Hsieh CI, Tsou MH, Lin CY, Huang AT. Improvement of local control of T3 and T4 nasopharyngeal carcinoma by hyperfractionated radiotherapy and concomitant chemotherapy. Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):344-52.</citation>
    <PMID>12023138</PMID>
  </reference>
  <reference>
    <citation>Toita T, Ogawa K, Kamata M, Kojya S, Itokazu T, Kakinohana Y, Iraha S, Yoshinaga M, Zukeran Y, Sawada S. Hyperfractionated radiotherapy followed by adjuvant chemotherapy for nasopharyngeal cancer: report of seven cases. Jpn J Clin Oncol. 1999 Mar;29(3):160-3.</citation>
    <PMID>10225700</PMID>
  </reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 25, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 24, 2016</last_update_submitted>
  <last_update_submitted_qc>May 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

